184 related articles for article (PubMed ID: 16450809)
1. Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy.
Sackner-Bernstein J
Clin Cardiol; 2005 Nov; 28(11 Suppl 1):I19-27. PubMed ID: 16450809
[TBL] [Abstract][Full Text] [Related]
2. Practical algorithms for pharmacologic management of the post myocardial infarction patient.
Reiffel JA; ;
Clin Cardiol; 2005 Nov; 28(11 Suppl 1):I28-37. PubMed ID: 16450810
[TBL] [Abstract][Full Text] [Related]
3. Sudden cardiac death and the role of medical therapy.
Arshad A; Mandava A; Kamath G; Musat D
Prog Cardiovasc Dis; 2008; 50(6):420-38. PubMed ID: 18474285
[TBL] [Abstract][Full Text] [Related]
4. Potential novel pharmacological therapies for myocardial remodelling.
Landmesser U; Wollert KC; Drexler H
Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews.
Al-Gobari M; Al-Aqeel S; Gueyffier F; Burnand B
BMJ Open; 2018 Jul; 8(7):e021108. PubMed ID: 30056380
[TBL] [Abstract][Full Text] [Related]
6. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?
van der Horst IC; Voors AA; van Veldhuisen DJ
Clin Res Cardiol; 2007 Apr; 96(4):193-5. PubMed ID: 17294352
[No Abstract] [Full Text] [Related]
7. Pharmacotherapy to reduce arrhythmic mortality.
Vora A; Kulkarni S
Indian Heart J; 2014; 66 Suppl 1(Suppl 1):S113-9. PubMed ID: 24568822
[TBL] [Abstract][Full Text] [Related]
8. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists?
Hoppe UC
Clin Res Cardiol; 2007 Apr; 96(4):196-8. PubMed ID: 17294351
[No Abstract] [Full Text] [Related]
9. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
10. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
11. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
Lee HY; Cooke CE; Robertson TA
J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
[TBL] [Abstract][Full Text] [Related]
12. Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death.
Boriani G; Valzania C; Diemberger I; Biffi M; Martignani C; Bertini M; Ziacchi M; Domenichini G; Saporito D; Rapezzi C; Branzi A
Expert Opin Investig Drugs; 2007 May; 16(5):605-23. PubMed ID: 17461735
[TBL] [Abstract][Full Text] [Related]
13. Real-world algorithms for the optimal use of drugs and devices in the patient post myocardial infarction and the future of post myocardial infarction management.
Rudo TJ; Kowey PR
Clin Cardiol; 2005 Nov; 28(11 Suppl 1):I58-63. PubMed ID: 16450814
[TBL] [Abstract][Full Text] [Related]
14. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS
Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
[TBL] [Abstract][Full Text] [Related]
16. Post-Myocardial Infarction Heart Failure.
Bahit MC; Kochar A; Granger CB
JACC Heart Fail; 2018 Mar; 6(3):179-186. PubMed ID: 29496021
[TBL] [Abstract][Full Text] [Related]
17. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.
Korhonen MJ; Robinson JG; Annis IE; Hickson RP; Bell JS; Hartikainen J; Fang G
J Am Coll Cardiol; 2017 Sep; 70(13):1543-1554. PubMed ID: 28935030
[TBL] [Abstract][Full Text] [Related]
18. Neurohormonal intervention to reduce sudden cardiac death in heart failure: what is the optimal pharmacologic strategy?
Squire I
Heart Fail Rev; 2004 Oct; 9(4):337-45; discussion 347-51. PubMed ID: 15886979
[TBL] [Abstract][Full Text] [Related]
19. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of age.
Setoguchi S; Glynn RJ; Avorn J; Levin R; Winkelmayer WC
Am J Cardiol; 2007 Oct; 100(7):1061-7. PubMed ID: 17884362
[TBL] [Abstract][Full Text] [Related]
20. Hospital protocols and evidence-based therapies: the importance of integrating aldosterone blockade into the management of patients with post-acute myocardial infarction heart failure.
Fonarow GC
Clin Cardiol; 2006 Jan; 29(1):4-8. PubMed ID: 16477770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
